Page last updated: 2024-08-17

spironolactone and losartan

spironolactone has been researched along with losartan in 67 studies

Research

Studies (67)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.99)	18.2507
2000's	32 (47.76)	29.6817
2010's	29 (43.28)	24.3611
2020's	4 (5.97)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C	1
Greene, EL; Hostetter, TH; Kren, S	1
Puddefoot, JR; Vinson, GP; Xiao, F	1
Henger, A; Hulter, HN; Krapf, R; Riesen, WF; Tutt, P	1
Miller, AB; Srivastava, P	1
Felder, RB; Francis, J; Weiss, RM; Zhang, ZH	1
Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D	1
Funder, JW; Mardini, M; Mihailidou, AS; Raison, M	1
Weber, MA	1
Flack, JM; Garthwaite, S; Kleiman, JH; Krause, SL; Oparil, S; Pratt, JH; Roniker, B; Saunders, E; Workman, D; Yang, Y	1
Ben-Yehuda, O	1
de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG	1
Aviram, M; Coleman, R; Hamoud, S; Hayek, T; Kaplan, M; Keidar, S; Pavlotzky, E	1
Amador, N; Encarnación, JJ; Guízar, JM; López, M; Rodríguez, L	1
Jaffe, IZ; Mendelsohn, ME	1
Kauffmann, R; Orozco, R; Venegas, JC	1
Davidson, RC; Krause, SL; MacDonald, TM; Patrick, JL; Roniker, B; Ruilope, LM; Weinberger, MH; White, WB	1
Aldigier, JC; Brown, NJ; Fogo, AB; Kanjanbuch, T; Ma, LJ	1
Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y	1
Ashby, MJ; Brown, MJ; Hood, SJ; Taylor, KP	1
Baumann, M; Boudier, HA; Heemann, U; Hermans, JJ; Janssen, BJ; Peutz-Kootstra, C; Smits, JF; Witzke, O	1
Milan, A; Mulatero, P; Veglio, F	1
Adamczak, M; Geldyyev, A; Gross, ML; Koleganova, N; Piecha, G; Ritz, E	1
Amann, K; Hartner, A; Hilgers, KF; Klanke, B; Melk, A; Steinbach, MP; Westhoff, JH	1
Lindner, T	1
Gabor, A; Leenen, FH	1
Lim, BH; Park, JB; Park, YM; Touyz, RM	1
Adamson, GE; Brandish, PE; Chen, H; Flores, OA; Forest, TW; Gatto, NT; Hershey, JC; Ma, BK; Molon-Noblot, S; Szczerba, P; Zwierzynski, I	1
Blankesteijn, WM; Daemen, MJ; Fujimoto, A; Fujimoto, S; Hofstra, L; Isobe, S; Li, P; Lovhaug, D; Narula, J; Narula, N; Petrov, A; Pitt, B; Reutelingsperger, C; Smits, JF; van den Borne, SW; Vannan, MA; Wong, ND; Zandbergen, HR; Zannad, F	1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kobayashi, T; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H	1
Che, ZQ; Gao, PJ; Han, WQ; Liu, JJ; Wu, LY; Wu, YJ; Zhang, J; Zhou, HY; Zhu, DL	1
Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL	1
Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA	1
Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K	1
Barretti, D; Da Silva, ND; de Oliveira, EM; Do Carmo, EC; Fernandes, T; Irigoyen, MC; Koike, D; Mattos, KC; Melo, SF; Rosa, KT; Wichi, RB	1
Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J	1
Ashek, A; Bailey, MA; Bellamy, CO; Flatman, PW; Harmar, AJ; Kenyon, CJ; Menzies, RI; Mullins, JJ; Mullins, LJ	1
Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S	1
da H Silva, A; dos Santos, MC; Ferraz, EF; Marques Neto, SR; Nascimento, JH	1
Cassis, LA; Daugherty, A; Gong, MC; Guo, Z; Liu, S; Pearson, KJ; Xie, Z	1
Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M	1
Bartelds, B; Berger, RM; Borgdorff, MA; Dickinson, MG; Steendijk, P	1
Alexander, T; Baylis, C; Cunningham, MW; Fekete, A; Masilamani, SM; Sasser, JM; Shaw, S; West, CA	1
Gai, L; Xie, Y; Yan, M	1
Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E	1
Adams-Huet, B; Molina, C; Nguyen, M; Toto, RD; Van Buren, PN	1
Fried, LF; Seliger, SL	1
Janssen, PM; Murray, JD; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Schill, KE; Schultz, EJ; Tran, T	1
Balderia, PG; Patel, M; Stanek, M; Wongrakpanich, S	1
Gómez Casal, V; Lage Cendon, L; Lago Preciado, G; Vara Adrio, S	1
Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP	1
Adams-Huet, B; Srivastava, A; Toto, RD; Vega, GL	1
Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA	1
Alves, PH; Castro, CH; Colugnati, DB; Macedo, LM; Mendes, EP; Nunes, AD; Pedrino, GR; Santos, RA; Souza, AP	1
Bakris, GL; Berman, L; Bushinsky, DA; Freeman, MW; Garza, D; Lainscak, M; Mayo, MR; Pitt, B; Weir, MR; Zawadzki, R	1
Balogh, DB; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lakat, T; Lenart, L; Molnar, A; Sparding, N; Szabo, AJ; Szkibinszkij, E; Vannay, A; Wagner, L	1
Aggarwal, D; Singh, G	1
Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM	1
Koiwa, H; Matsushima, S; Morisaki, H; Morisaki, T; Naya, M; Tsujinaga, S; Yokota, T	1
Birn, H; Christensen, JH; Mårup, FH; Peters, CD	1

Reviews

3 review(s) available for spironolactone and losartan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. Cardiology clinics, 2001, Volume: 19, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan	2001
Clinical implications of aldosterone blockade. American heart journal, 2002, Volume: 144, Issue:5 Suppl Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Humans; Hypertension; Kidney Diseases; Losartan; Mineralocorticoid Receptor Antagonists; Potassium; Renin-Angiotensin System; Spironolactone	2002

Trials

12 trial(s) available for spironolactone and losartan

Article	Year
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:2 Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2002
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology, 2003, Apr-02, Volume: 41, Issue:7 Topics: Adult; Aldosterone; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People	2003
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. Journal of human hypertension, 2005, Volume: 19, Issue:4 Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diuretics; Double-Blind Method; Echocardiography; Electrocardiography, Ambulatory; Follow-Up Studies; Heart; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Obesity; Spironolactone; Sympathetic Nervous System; Treatment Outcome; Ventricular Remodeling	2005
Effects of eplerenone versus losartan in patients with low-renin hypertension. American heart journal, 2005, Volume: 150, Issue:3 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone	2005
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Enalapril; Female; Furosemide; Heart Failure; Humans; Hyperkalemia; Losartan; Male; Middle Aged; Potassium; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone	2005
The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation, 2007, Jul-17, Volume: 116, Issue:3 Topics: Aged; Aldosterone; Amiloride; Bendroflumethiazide; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Renin; Single-Blind Method; Sodium Chloride Symporter Inhibitors; Spironolactone	2007
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:12 Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bicarbonates; Blood Pressure; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypertension; Lisinopril; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Renin-Angiotensin System; Spironolactone	2009
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascular; Eplerenone; Female; Humans; Hypertension; Leukocytes; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nifedipine; Nitroglycerin; rho-Associated Kinases; Spironolactone; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation	2012
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2014, Volume: 9, Issue:2 Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Creatinine; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Female; Humans; Hyperkalemia; Lisinopril; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Renin-Angiotensin System; Risk Factors; Sodium; Spironolactone; Texas; Time Factors; Treatment Outcome	2014
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2016, Volume: 64, Issue:6 Topics: Diabetic Nephropathies; Female; Humans; Lipoproteins; Losartan; Male; Middle Aged; Spironolactone; Triglycerides	2016
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC heart failure, 2018, Volume: 5, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hyperkalemia; Losartan; Potassium; Retrospective Studies; Spironolactone; Stroke Volume; Time Factors; Treatment Outcome	2018
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled BMJ open, 2022, Feb-21, Volume: 12, Issue:2 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperkalemia; Losartan; Male; Mineralocorticoid Receptor Antagonists; Polymers; Potassium; Quality of Life; Renal Insufficiency, Chronic; Renin-Angiotensin System; Spironolactone	2022

Other Studies

52 other study(ies) available for spironolactone and losartan

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3 Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs	2013
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:1 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phenomena; Biochemistry; Biphenyl Compounds; Cardiomyopathies; Collagen; Endomyocardial Fibrosis; Fibrosis; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Imidazoles; Losartan; Microscopy, Polarization; Polymerase Chain Reaction; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Tetrazoles	1995
Role of aldosterone in the remnant kidney model in the rat. The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4 Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Body Weight; Disease Models, Animal; Enalapril; Imidazoles; Kidney; Kidney Diseases; Losartan; Male; Mineralocorticoid Receptor Antagonists; Nephrectomy; Organ Size; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles	1996
Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. The Journal of endocrinology, 2000, Volume: 165, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Cell Division; Cells, Cultured; Cytochrome P-450 CYP11B2; Drug Synergism; Losartan; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Spironolactone; Stimulation, Chemical	2000
Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. The Journal of laboratory and clinical medicine, 2000, Volume: 136, Issue:5 Topics: Acid-Base Equilibrium; Acidosis; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Chronic Disease; Electrolytes; Female; Humans; Hydrocortisone; Losartan; Male; Nitrogen; Spironolactone	2000
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:1 Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Echocardiography; Heart Failure; Injections, Intra-Arterial; Injections, Intravenous; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Neurons; Paraventricular Hypothalamic Nucleus; Pressoreceptors; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Spironolactone	2002
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:2 Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Eplerenone; Heart Ventricles; Hyperaldosteronism; Losartan; Magnesium; Male; Membrane Potentials; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Potassium; Rabbits; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Ventricular Function	2002
Hypertension, angiotensin II, aldosterone, and race. Journal of the American College of Cardiology, 2003, Apr-02, Volume: 41, Issue:7 Topics: Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Eplerenone; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People	2003
Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clinical and experimental pharmacology & physiology, 2003, Volume: 30, Issue:10 Topics: Animals; Cicatrix; Collagen; Hydralazine; Losartan; Male; Myocardial Infarction; Myocardium; Organ Size; Rats; Rats, Wistar; Spironolactone	2003
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation, 2004, May-11, Volume: 109, Issue:18 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cell Line; Enzyme Induction; Eplerenone; Hormone Antagonists; Humans; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Macrophages, Peritoneal; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Phosphoproteins; Protein Transport; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Superoxides	2004
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circulation research, 2005, Apr-01, Volume: 96, Issue:6 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Adenoviridae; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Aorta; Cell Line, Transformed; Coronary Vessels; Gene Expression Profiling; Gene Expression Regulation; Genes, Reporter; Genetic Vectors; Humans; Hydrocortisone; Losartan; Mammary Tumor Virus, Mouse; Models, Biological; Muscle, Smooth, Vascular; Myocardial Ischemia; Myocytes, Smooth Muscle; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Spironolactone; Transcription, Genetic; Transduction, Genetic	2005
[Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. Revista medica de Chile, 2005, Volume: 133, Issue:8 Topics: Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Humans; Hyperkalemia; Hypertension; Losartan; Severity of Illness Index; Spironolactone	2005
Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:11 Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephritis; Kidney Function Tests; Losartan; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Spironolactone; Transcription, Genetic; Transforming Growth Factor beta	2005
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. Journal of hypertension, 2007, Volume: 25, Issue:12 Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; Collagen; DNA Primers; Heart; Hypertension; Kidney; Losartan; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Spironolactone	2007
Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio". Circulation, 2008, Feb-05, Volume: 117, Issue:5 Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bendroflumethiazide; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Losartan; Sodium Chloride Symporter Inhibitors; Spironolactone	2008
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. American journal of physiology. Renal physiology, 2008, Volume: 295, Issue:1 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type IV; Desmin; Dihydralazine; Drug Therapy, Combination; Glomerulonephritis; Immunohistochemistry; Kidney Glomerulus; Losartan; Male; Mineralocorticoid Receptor Antagonists; Nephrectomy; NF-kappa B; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Spironolactone; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2008
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Desoxycorticosterone; Heart Ventricles; Humans; Hydralazine; Hydrochlorothiazide; Hypertension, Renal; Kidney; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Nephrosclerosis; p38 Mitogen-Activated Protein Kinases; Rats; Renin; Reserpine; RNA, Messenger; Spironolactone	2008
Aliskiren combined with losartan in diabetes and nephropathy. The New England journal of medicine, 2008, Sep-04, Volume: 359, Issue:10 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Proteinuria; Renin; Spironolactone	2008
Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:3 Topics: Aldosterone; Amiloride; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cerebrospinal Fluid; Diuretics; Dose-Response Relationship, Drug; Eplerenone; Heart Rate; Hypertension; Injections, Intraventricular; Losartan; Ouabain; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Sodium; Spironolactone	2009
Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. Journal of Korean medical science, 2008, Volume: 23, Issue:6 Topics: Acetophenones; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Blood Pressure; Hypertension; Kidney; Losartan; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Organ Size; Oxidative Stress; Protein Subunits; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium Chloride; Spironolactone; Superoxides	2008
Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure. Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:1 Topics: Animals; Blood Pressure; Eplerenone; Heart; Hypertension; Losartan; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Spironolactone	2009
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC. Cardiovascular imaging, 2009, Volume: 2, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carbocyanines; Cardiovascular Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Spironolactone; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling	2009
Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. Journal of medical virology, 2009, Volume: 81, Issue:9 Topics: Aged; Antihypertensive Agents; Asian People; Case-Control Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Hypertension; Longitudinal Studies; Losartan; Male; Middle Aged; Spironolactone	2009
Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone. Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:5-6 Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Collagen; Connective Tissue; Diuretics; Drug Evaluation, Preclinical; Elastin; Hypertension; Losartan; Muscle, Smooth, Vascular; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spironolactone	2009
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2 Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Cell Communication; Cellular Senescence; Connexin 43; Disease Models, Animal; Echocardiography, Doppler; Electrocardiography; Epicardial Mapping; Eplerenone; Female; Fibrosis; Heart Conduction System; Heart Diseases; Losartan; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Myocardium; Renin-Angiotensin System; Spironolactone; Ventricular Function, Left; Ventricular Function, Right	2010
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone; Fluorescent Antibody Technique; Intracellular Signaling Peptides and Proteins; Losartan; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Nephrosis, Lipoid; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Time Factors	2010
Anabolic steroid associated to physical training induces deleterious cardiac effects. Medicine and science in sports and exercise, 2011, Volume: 43, Issue:10 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Anabolic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Collagen Type III; Cytochrome P-450 CYP11B2; Heart Ventricles; Losartan; Male; Mineralocorticoid Receptor Antagonists; Nandrolone; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Spironolactone; Stroke Volume; Swimming	2011
Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. PloS one, 2012, Volume: 7, Issue:4 Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP1A1; Hydrochlorothiazide; Hypertension; Kidney Tubules, Distal; Losartan; Male; Microvessels; Natriuresis; Rats; Rats, Transgenic; Renin; Sodium Chloride Symporters; Spironolactone	2012
Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. The Journal of surgical research, 2013, Volume: 179, Issue:1 Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Cell Proliferation; Female; Fibrosis; Hepatectomy; Hepatocytes; Liver; Liver Regeneration; Losartan; Mineralocorticoid Receptor Antagonists; Models, Animal; Neovascularization, Physiologic; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Smad2 Protein; Spironolactone; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A	2013
The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction. Acta physiologica (Oxford, England), 2013, Volume: 208, Issue:2 Topics: Anabolic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Heart Diseases; Losartan; Male; Mineralocorticoid Receptor Antagonists; Nandrolone; Nandrolone Decanoate; Random Allocation; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone	2013
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:7 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Aortic Rupture; Apoptosis; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Elastin; Enalapril; Eplerenone; Losartan; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors	2013
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. Journal of diabetes research, 2013, Volume: 2013 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Heart; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Spironolactone	2013
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. International journal of cardiology, 2013, Nov-05, Volume: 169, Issue:3 Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Male; Random Allocation; Rats; Rats, Wistar; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Right	2013
Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathways. American journal of physiology. Regulatory, integrative and comparative physiology, 2013, Nov-15, Volume: 305, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 5; Diuretics; Enalapril; Epithelial Sodium Channels; Female; Kidney Medulla; Losartan; Nephrons; Nifedipine; Pregnancy; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Sodium; Sodium Nitrite; Spironolactone; Vasodilation; Vasodilator Agents	2013
[Effect of angiotensin II and aldosterone on the proliferation of cardiac fibroblasts in rats]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2013, Volume: 38, Issue:9 Topics: Aldosterone; Angiotensin II; Animals; Cell Proliferation; Collagen; Fibroblasts; Losartan; Myocardium; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spironolactone	2013
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Reperfusion Injury; Myocardium; Nandrolone; Nandrolone Decanoate; Physical Conditioning, Animal; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Reperfusion Injury; Spironolactone; Steroids; Ventricular Function, Left	2014
Serum potassium in dual renin-angiotensin-aldosterone system blockade. Clinical journal of the American Society of Nephrology : CJASN, 2014, Volume: 9, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Diuretics; Female; Humans; Lisinopril; Losartan; Male; Potassium; Renin-Angiotensin System; Spironolactone	2014
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PloS one, 2014, Volume: 9, Issue:2 Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; Glucocorticoids; Humans; Lisinopril; Losartan; Male; Mice; Mice, Inbred mdx; Muscle Contraction; Muscle Weakness; Muscle, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Myocardium; Prednisolone; Spironolactone; Utrophin	2014
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydrogenase deficiency. BMJ case reports, 2015, Mar-05, Volume: 2015 Topics: Aged; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Female; Glucosephosphate Dehydrogenase Deficiency; Heart Failure; Humans; Losartan; Metoprolol; Spironolactone	2015
[Ivabradine poisoning with suicide intention]. Medicina intensiva, 2015, Volume: 39, Issue:9 Topics: Adult; Antidotes; Benzazepines; Bradycardia; Calcium Gluconate; Combined Modality Therapy; Drug Overdose; Electrocardiography; Female; Humans; Ivabradine; Loperamide; Losartan; Norepinephrine; Pacemaker, Artificial; Poisoning; Spironolactone; Suicide, Attempted	2015
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. Clinical and experimental pharmacology & physiology, 2015, Volume: 42, Issue:11 Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Diseases; Hypertension; Lipid Peroxidation; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; Rats, Sprague-Dawley; Renin-Angiotensin System; Signal Transduction; Spironolactone; Time Factors; Tyrosine	2015
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. Hypertension (Dallas, Tex. : 1979), 2016, Volume: 68, Issue:3 Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; Losartan; Male; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Renin-Angiotensin System; Role; Spironolactone; Vasoconstriction	2016
Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Mar-23, Volume: 50, Issue:4 Topics: Amlodipine; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Calcium Channel Blockers; Captopril; Coronary Vessels; Losartan; Male; Mineralocorticoid Receptor Antagonists; Models, Animal; Peptide Fragments; Rats, Wistar; Reproducibility of Results; Spironolactone; Time Factors; Vasoconstriction; Vasodilation	2017
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. The Journal of physiology, 2019, Volume: 597, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Losartan; Male; Mannitol; Mineralocorticoid Receptor Antagonists; Proto-Oncogene Proteins c-sis; Ramipril; Rats, Wistar; Renin-Angiotensin System; Spironolactone	2019
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:4 Topics: Animals; Catalase; Cytokines; Glutathione; Kidney; Kidney Diseases; Losartan; Male; Rats, Wistar; Renin-Angiotensin System; Reperfusion Injury; Spironolactone; Thiobarbituric Acid Reactive Substances	2020
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020, Jun-01, Volume: 1146 Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan	2020
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure. The Canadian journal of cardiology, 2022, Volume: 38, Issue:3 Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; Genetic Testing; Heart Failure; Humans; Loeys-Dietz Syndrome; Losartan; Male; Middle Aged; Mutation; Pulmonary Edema; Receptor, Transforming Growth Factor-beta Type I; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left	2022